Test your knowladge on epcoritamab

Based on the EPCORE NHL-1 trial for epcoritamab, which of the following is most appropriate to tell a patient regarding the risk of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)?

CRS and ICANS are rare and occur during the first hour of the cycle 1, day 1.

CRS and ICANS are common and usually occur with cycle 1, day 8.

CRS and ICANS, which are common and severe (grade ≥3), can occur at any time.

CRS and ICANS are usually low grade and occur within the first few days following therapy.

Which of the following premedications is NOT needed before initiating treatment with a CD3 x CD20 T-cell–engaging bispecific antibody, such as epcoritamab, to reduce the risk of adverse effects?

Antipyretic

Antihistamine

Corticosteroid

Anticoagulant

Bendamustine can be given as a salvage combination therapy with rituximab and polatuzumab vedotin as a bridging therapy before leukapheresis is completed.

True

False